🏢 官网IRSPRYCodex · 实盘不做把握 9/10
北京时间·🕒 发布 08-03 19:30:10(美东 07:30)·⟳ 抓取 08-03 19:30:23 +13s·⚡ 决策 08-04 11:27:32 +15h57m·84.3 天前
ARS Pharmaceuticals预告8月13日召开电话会并披露二季度业绩
本次只是公司IR发布的电话会和业绩披露日程预告，未披露二季度财务数据、指引调整、商业化进展或战略内容。
📄 原文SPRY↗ 原文
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedi…
不做 ARS Pharmaceuticals（SPRY.US）
仅为电话会和二季度业绩披露日程预告，未披露业绩、指引或战略内容，当前没有可交易方向。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次只是公司IR发布的电话会和业绩披露日程预告，未披露二季度财务数据、指引调整、商业化进展或战略内容。
主要风险
- 若8月13日正式电话会披露超预期战略或业绩数据，应由新信号重新研判。
原文全文
展开原文 · 1,846 字
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Thursday, August 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. During the call, Donn Casale, President and Chief Executive Officer, will outline the Company’s updated strategic priorities and report second quarter 2026 financial results.
Dial-in information for conference participants may be obtained by
registering for the event
. To access the webcast and slides, please visit the
Events & Presentations
page in the Investors & Media section of the Company’s
website
. A replay of the webcast will be available for 30 days following the event.
About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing
neffy
®
(trade name
EUR
neffy
®
in the EU and 优敏速
®
in China), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit
www.ars-pharma.com
.
ARS Investor Contact:
Monique Allaire, THRUST
monique@thrustsc.com
ARS Media Contact:
Christy Curran, Sam Brown Inc.
615.414.8668
christycurran@sambrown.com
Dial-in information for conference participants may be obtained by
registering for the event
. To access the webcast and slides, please visit the
Events & Presentations
page in the Investors & Media section of the Company’s
website
. A replay of the webcast will be available for 30 days following the event.
About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing
neffy
®
(trade name
EUR
neffy
®
in the EU and 优敏速
®
in China), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit
www.ars-pharma.com
.
ARS Investor Contact:
Monique Allaire, THRUST
monique@thrustsc.com
ARS Media Contact:
Christy Curran, Sam Brown Inc.
615.414.8668
christycurran@sambrown.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。